Open AccessBevacizumab
Author(s) -
KazaziHyseni Filis,
Beijnen Jos H.,
Schellens Jan H. M.
Publication year - 2010
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2009-0317
Subject(s) - bevacizumab , medicine , medical physics , investigational drugs , pharmacology , oncology , clinical trial , intensive care medicine , chemotherapy
Learning Objectives After completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non‐oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab. Describe the pharmacology of bevacizumab and its mechanism of action in order to predict degrees of patient response.This article is available for continuing medical education credit at CME.TheOncologist.com .